Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-041423
Filing Date
2025-03-18
Accepted
2025-03-18 17:20:06
Documents
2
Period of Report
2025-03-18

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1603
2 EX-24.1 klrs-ex24_1.htm EX-24.1 13490
  Complete submission text file 0000950170-25-041423.txt   16694
Mailing Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301
Business Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301 650-249-2727
Kalaris Therapeutics, Inc. (Issuer) CIK: 0001754068 (see all company filings)

EIN.: 831971007 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005
Business Address
Oxtoby Andrew (Reporting) CIK: 0001765473 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39409 | Film No.: 25749617